血脂与透析患者残余肾功能的关系
The Association between Blood Lipids and Residual Renal Function in Dialysis Patients
DOI: 10.12677/acm.2024.1461904, PDF,   
作者: 刘 静:包头医学院研究生院,内蒙古 包头;史应进*:包头医学院第一附属医院肾内科,内蒙古 包头
关键词: 血脂高脂血症血液透析腹膜透析残余肾功能Blood Lipids Hyperlipidemia Hemodialysis Peritoneal Dialysis Residual Renal Function
摘要: 目的:探讨血脂与透析患者残余肾功能的关系。方法:回顾性分析我院2018年9月~2020年9月收治的200例ESRD病人的临床病历资料,根据透析方式的不同分为血液透析组(100例)和腹膜透析组(100例),观察透析患者中血脂和残余肾功能的变化以及透析患者治疗24个月内血脂变化。结果:腹透患者总胆固醇和低密度脂蛋白较血透患者显著升高(P < 0.01)。透析治疗初期残余肾功能无明显变化(P > 0.05)。血透患者与腹透患者第12月时RRF较同组透析初月时下降(P < 0.05)。血透患者与腹透患者第12月时总胆固醇和低密度脂蛋白较透析初月时比较显著下降(P < 0.01)。血透患者RRF下降速率与TC (r = 0.503, P < 0.05)、LDL ( r = 0.0.669, P < 0.05)均呈正相关,腹透患者RRF下降速率与TC (r = 0.894, P < 0.05)、LDL (r = 0.860, P < 0.05)均呈正相关。结论:① 腹透患者和血透患者的RRF随着透析时间的延长而降低,血透患者的残余肾功能下降速率大于腹透患者的残余肾功能下降速率。② 透析患者残余肾功能下降速率与TC、LDL水平呈正相关,高血脂对RRF降低有影响。③ ESRD患者随着透析治疗时间的延长出现血脂异常。
Abstract: Objective: To explore the correlation between blood lipid levels and residual renal function in patients undergoing hemodialysis. Methods: The clinical data of 200 ESRD patients admitted to our hospital from September 2018 to September 2020 were retrospectively analyzed. According to the different dialysis methods, the patients were divided into hemodialysis group (100 cases) and peritoneal dialysis group (100 cases). The changes of blood lipid and residual renal function in dialysis patients and the changes of blood lipid in dialysis patients within 24 months of treatment were observed. Results: Total cholesterol and low density lipoprotein in PD patients were significantly higher than those in MHD patients (P < 0.001). There was no significant change in residual renal function at the beginning of dialysis treatment (p > 0.05). The RRF of hemodialysis and peritoneal dialysis patients in the 12th month was lower than that in the first month of dialysis in the same group (P < 0.05). The levels of total cholesterol and low density lipoprotein in hemodialysis patients and peritoneal dialysis patients at the 12th month were significantly lower than those at the beginning of dialysis (P < 0.01). The decline rate of RRF in hemodialysis patients was positively correlated with TC (r = 0.503, P < 0.05) and LDL (r = 0.0.669, P < 0.05), and the decline rate of RRF in peritoneal dialysis patients was positively correlated with TC (r = 0.894, P < 0.05) and LDL (r = 0.860, P < 0.05). Conclusion: ① The RRF of PD and HD patients decreased with the prolongation of dialysis time, and the rate of decline of residual renal function in HD patients was greater than that in PD patients. ② The decline rate of residual renal function in dialysis patients is positively correlated with TC and LDL levels, and hyperlipidemia has an impact on RRF reduction. ③ ESRD patients have dyslipidemia with the extension of dialysis treatment time.
文章引用:刘静, 史应进. 血脂与透析患者残余肾功能的关系[J]. 临床医学进展, 2024, 14(6): 1245-1251. https://doi.org/10.12677/acm.2024.1461904

参考文献

[1] 李辛, 吕祥, 梁志江. 不同透析方式对残余肾功能的影响及其与预后的关系研究[J]. 中国医学工程, 2018, 26(12): 29-32.
[2] 任伟, 兰雷. 透析病人保护残余肾功能的重要性[J]. 国外医学(老年医学分册), 2007, 28(4): 185-188.
[3] 孙春晓, 郭兆安. 慢性肾脏病血脂代谢紊乱的影响因素及其机制的研究进展[J]. 中国中西医结合肾病杂志, 2014, 15(6): 546-548.
[4] 刘爱英, 冯国徵, 孙秀丽. 血液透析与腹膜透析对终末期肾病患者血脂、氧化应激及炎症因子的影响[J]. 中国煤炭工业医学杂志, 2020, 23(1): 57-61.
[5] 吴娜. 第一年残余肾功能下降速率和腹膜透析患者死亡风险的研究[D]: [硕士学位论文]. 广州: 南方医科大学, 2022.
[6] 张琪琦, 安惠霞, 姜国涛, 等. 高血脂对腹膜透析患者的残余肾功能影响[J]. 中国中西医结合肾病杂志, 2007, 8(8): 466-468.
[7] 韩庆烽, 郑丹侠, 齐颖, 等. 腹膜透析病人残余肾功能减退的影响因素[J]. 北京医科大学学报, 2000, 32(1): 87, 89.
[8] 赵飞, 潘志铣, 曾瑞坤, 等. 血液透析患者残余肾功能与血压的相关性分析[J]. 数理医药学杂志, 2020, 33(7): 957-959.
[9] Schwarz, U., Buzello, M., Ritz, E., Stein, G., Raabe, G., Wiest, G., et al. (2000) Morphology of Coronary Atherosclerotic Lesions in Patients with End-Stage Renal Failure. Nephrology Dialysis Transplantation, 15, 218-223. [Google Scholar] [CrossRef] [PubMed]
[10] Campese, V.M. (2014) Dyslipidemia and Progression of Kidney Disease: Role of Lipid-Lowering Drugs. Clinical and Experimental Nephrology, 18, 291-295. [Google Scholar] [CrossRef] [PubMed]
[11] Schaeffner, E.S., Kurth, T., Curhan, G.C., Glynn, R.J., Rexrode, K.M., Baigent, C., et al. (2003) Cholesterol and the Risk of Renal Dysfunction in Apparently Healthy Men. Journal of the American Society of Nephrology, 14, 2084-2091. [Google Scholar] [CrossRef] [PubMed]
[12] Hovind, P., Rossing, P., Tarnow, L., Smidt, U.M. and Parving, H. (2001) Remission and Regression in the Nephropathy of Type 1 Diabetes When Blood Pressure Is Controlled Aggressively11see Editorial by Steffes, P. 378. Kidney International, 60, 277-283. [Google Scholar] [CrossRef] [PubMed]
[13] 孟梅霞, 张莉, 傅艳平, 等. 慢性肾脏病与血脂异常关系的调查研究[J]. 陕西医学杂志, 2014(9): 1157-1159.
[14] Abrass, C.K. (2004) Cellular Lipid Metabolism and the Role of Lipids in Progressive Renal Disease. American Journal of Nephrology, 24, 46-53. [Google Scholar] [CrossRef] [PubMed]
[15] Chen, S., Hung, C., Kuo, M., Lee, J., Chiu, Y., Chang, J., et al. (2013) Association of Dyslipidemia with Renal Outcomes in Chronic Kidney Disease. PLOS ONE, 8, e55643. [Google Scholar] [CrossRef] [PubMed]
[16] 李晓燕. CKD高脂血症患者中医证候特点的研究[D]: [硕士学位论文]. 济南: 山东中医药大学, 2012.
[17] Massy, Z.A., Kim, Y., Guijarro, C., Kasiske, B.L., Keane, W.F. and O’Donnell, M.P. (2000) Low-Density Lipoprotein-Induced Expression of Interleukin-6, a Marker of Human Mesangial Cell Inflammation: Effects of Oxidation and Modulation by Lovastatin. Biochemical and Biophysical Research Communications, 267, 536-540. [Google Scholar] [CrossRef] [PubMed]
[18] Wagner, A.H., Köhler, T., Rückschloss, U., Just, I. and Hecker, M. (2000) Improvement of Nitric Oxide–dependent Vasodilatation by Hmg-Coa Reductase Inhibitors through Attenuation of Endothelial Superoxide Anion Formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 20, 61-69. [Google Scholar] [CrossRef] [PubMed]
[19] Ruan, X.Z., Moorhead, J.F., Tao, J.L., Ma, K.L., Wheeler, D.C., Powis, S.H., et al. (2006) Mechanisms of Dysregulation of Low-Density Lipoprotein Receptor Expression in Vascular Smooth Muscle Cells by Inflammatory Cytokines. Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 1150-1155. [Google Scholar] [CrossRef] [PubMed]
[20] Rovin, B.H. and Tan, L.C. (1993) LDL Stimulates Mesangial Fibronectin Production and Chemoattractant Expression. Kidney International, 43, 218-225. [Google Scholar] [CrossRef] [PubMed]
[21] Bianchi, S., Bigazzi, R., Caiazza, A. and Campese, V.M. (2003) A Controlled, Prospective Study of the Effects of Atorvastatin on Proteinuria and Progression of Kidney Disease. American Journal of Kidney Diseases, 41, 565-570. [Google Scholar] [CrossRef] [PubMed]
[22] Bussolati, B., Deregibus, M.C., Fonsato, V., Doublier, S., Spatola, T., Procida, S., et al. (2005) Statins Prevent Oxidized LDL-Induced Injury of Glomerular Podocytes by Activating the Phosphatidylinositol 3-Kinase/AKT-Signaling Pathway. Journal of the American Society of Nephrology, 16, 1936-1947. [Google Scholar] [CrossRef] [PubMed]
[23] Kagan, A., Elimalech, E., Lerner, Z., Fink, A. and Bar-Khayim, Y. (1997) Residual Renal Function Affects Lipid Profile in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 17, 243-249. [Google Scholar] [CrossRef
[24] Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J.F.E., Ruf, G., et al. (2005) Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis. New England Journal of Medicine, 353, 238-248. [Google Scholar] [CrossRef] [PubMed]